Press Releases
TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors
March 21, 2024
Full text of release ⓘ PDF Download
TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance
November 28, 2023
Full text of release ⓘ PDF Download
TOLREMO therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest
September 20, 2023
Full text of release ⓘ PDF Download
Press Release Archive
Upcoming Events
Bio€quity Europe 2024
May 12 - 14, 2024, San Sebastián, Spain
ASCO
May 31 - June 4, 2024, Chicago, Illinois
BIO International Convention
June 3 - 6, 2024, San Diego, California
In the News
TOLREMO RECEIVES CHF 1.5 MILLION FROM INNOSUISSE
December, 2023
TOLREMO secured a CHF 1.5 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start-up Innovation Project. The initiative supports start-ups prior to entering the market in the realisation of science-based innovation projects with significant potential. The grant is designed to expedite the market introduction of new products and services. TOLREMO has recently reached the clinic with its lead candidate, TT125-802, designed to prevent transcriptional cancer drug resistance and thereby improve the response rates and durability of targeted cancer treatments.
ⓘ Click here for more information: Innosuisse
DR. STEFANIE FLÜCKIGER IS A FINALIST FOR THE 2024 SEF.WOMENAWARD
nOVEMBER, 2023
TOLREMO’s co-founder and CEO Dr. Stefanie Flückiger-Mangual was selected as a finalist for the 2024 SEF.WomenAward. Presented by NZZ Konferenzen & Services as part of the Swiss Economic Forum, the Young Entrepreneur of the Year award honors women with an inspirational history of achievement in entrepreneurship. The award ceremony will take place on March 8th at The Circle in Zurich.
ⓘ Click here for press coverage and more information: SEF Awards
DR. STEFANIE FLÜCKIGER IS NOMINATED AT THE EUROPEAN LIFESTARS AWARD
OCTOBER, 2023
TOLREMO’s co-founder and CEO Dr. Stefanie Flückiger-Mangual was nominated for the European Lifestars Award - Women-Led Business Leader of the Year. Organized by LSX, the network for life science executive leaders, the award celebrates the achievements of individuals, teams and organizations that have shaped he landscape of the life science industry in the past year.
ⓘ Click here for press coverage and more information: European Lifestars Award
Dr. Stefanie Flückiger is Innovator of the Year
July, 2022
TOLREMO’s co-founder and CEO, Dr. Stefanie Flückiger-Mangual, received the Innovator of the Year award at the Female Innovation Forum for her pioneering work with TOLREMO in combatting drug resistance in cancer. Sponsored by BMW, the award recognizes innovators whose contributions have the potential to significantly bolster the Swiss economy through groundbreaking ideas and solutions.
ⓘ Click here for press coverage and more information: Start-Up Ticker and Blick
Swiss Startup Award, TOLREMO
September, 2021
TOLREMO has once again secured a spot among Switzerland's elite startups. The Top 100 Startup Awards recognize and honor trailblazing companies dedicated to creating meaningful impact globally.
ⓘ Click here for press coverage and more information: Top 100 Swiss Startups